DIRS.INFO The most relevant business & tech news

☆ Eli Lilly shares could be set for a big move if the Zepbound maker adds to its winning streak
▼ + stars: | 2024-10-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

Revenue from obesity treatment Zepbound is forecast to climb to $1.73 billion from $1.24 billion quarter over quarter. For the year, analysts expect Mounjaro sales to reach $4.58 billion, while Zepbound revenue is seen rising to $5.88 billion. The consensus view for combined sales of both drugs now stands at $30.19 billion, according to FactSet. Other key announcements A clinical trial is in progress that pits Zepbound against Novo Nordisk's Wegovy in obesity treatment. Beyond obesity, Lilly has begun treating patients with Kisunla, its Alzheimer's disease treatment.

Persons: Eli Lilly, Lilly, Seamus Fernandez, Morgan Stanley, Terence Flynn, David Risinger, Morgan Stanley's Flynn, Mounjaro, Cantor, Louise Chen, —, Fred Imbert Organizations: Investment, Food, Leerink, Novo Nordisk's, FDA, Kisunla Locations: U.S

☆ Weight loss care is leading IPO-hopeful Omada Health's latest growth surge as Ozempic boom continues
▼ + stars: | 2024-10-29 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +6 min

The startup says care for GLP-1 patients has become its most popular front door for new customers. AdvertisementLast spring, diabetes startup Omada Health said it wanted to help employers manage patients taking a blockbuster new class of weight-loss drugs. Omada Health's metabolic health program has now become the entry point for most new employers considering contracts with Omada Health, Duffy said. Launched in 2011, Omada provides virtual care for diabetes, hypertension, musculoskeletal care, and diabetes prevention, alongside obesity, to employers, health plans, and even health systems. The firm said GLP-1 drugs for obesity account for about 10% of all pharmacy spending.

Persons: —, Duffy, Omada, haven't, buzzy, Willis Towers Watson Organizations: Service, Omada Health, Business, Nordisk's Ozempic Locations: WeightWatchers, GLP

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia. Another study, published in August, found that semaglutide appeared to cut the risk of dementia in people with Type 2 diabetes. Type 2 diabetes is a risk factor for dementia and Alzheimer’s. The study found that patients prescribed semaglutide had a significantly lower risk for Alzheimer’s disease than those who had taken one of the seven other diabetes drugs. The biggest difference was seen when comparing patients who took semaglutide to those who took insulin: Semaglutide patients had a 70% lower risk of Alzheimer’s, the study found.

Persons: —, semaglutide, ”, Stephen Salloway, ” Salloway, Rong Xu, liraglutide, Xu, ” Xu, they’re, Salloway, they’ve, Donna Wilcock, there’s, ” Wilcock, Dr, Alberto Espay, Espay, What’s, “, ” Espay Organizations: Alzheimer’s Association, Conference, Novo Nordisk, Warren Alpert Medical, Brown University, Center, Artificial Intelligence, Case Western Reserve University School of Medicine, Drug Administration, ”, Alzheimer’s, Indiana University School of Medicine, University of Cincinnati College of Medicine Locations: Novo, Rhode Island, Ohio

☆ Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
▼ + stars: | 2024-10-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Novo Nordisk 's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday. Alzheimer's disease is often diagnosed in the mild dementia stage, when a person has significant trouble with memory and thinking. But the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. by 2050. Novo Nordisk, which did not fund the new Case Western study, is also examining semaglutide in a late-stage study on Alzheimer's patients. In the liraglutide research, data from a midstage trial found that the drug may slow the progression of Alzheimer's disease by protecting patients' brains.

Persons: Semaglutide, Dr, Rong Xu, it's, Xu, Eli Lilly, Wegovy, Eli Lilly's Organizations: Novo Nordisk, Alzheimer's Association, Case Western Reserve University, CNBC, Nordisk, Case, National Institutes of Health, GLP Locations: U.S, Novo

☆ Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
▼ + stars: | 2024-10-23 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. The FDA still has to make a final decision on whether to bar compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy. In a statement, the agency said it is reviewing the petition and will respond directly to Novo Nordisk. The active ingredient in Wegovy and Ozempic, semaglutide, has been in intermittent shortages over the past two years. Like Novo Nordisk, Eli Lilly has sued several weight loss clinics, medical spas and compounding pharmacies across the U.S. over the past year.

Persons: Wegovy, Danish drugmaker, semaglutide, Eli Lilly, Eli Lilly's, compounders Organizations: Novo Nordisk, Tuesday, Food and Drug Administration, FDA, Nordisk Locations: Novo, Danish, U.S

☆ Cramer's Lightning Round: Uranium Energy is 'the real deal'
▼ + stars: | 2024-10-14 | by ( Julie Coleman | ) www.cnbc.com time to read: 1 min

Stock Chart Icon Stock chart icon Novo Nordisk's year-to-date stock performance. Stock Chart Icon Stock chart icon Uranium Energy's year-to-date stock performance. Uranium Energy : "UEC's the real deal...It's going higher. We need more uranium. Stock Chart Icon Stock chart icon Halliburton's year-to-date stock performance.

Persons: Eli Lilly Organizations: Novo, Novo Nordisk, Uranium Energy, Halliburton

☆ Lightning Round: Stay away from Halliburton, says Jim Cramer
▼ + stars: | 2024-10-14 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Stay away from Halliburton, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: Vistra, Novo Nordisk, Uranium and Halliburton.

Persons: Jim Cramer Organizations: Halliburton, Novo Nordisk, Uranium Locations: Novo

☆ Ozempic is driving up the cost of your health care, whether you can get your hands on it or not
▼ + stars: | 2024-10-11 | by ( Jessica Dickler | ) www.cnbc.com time to read: +2 min

About 165 million Americans rely on employer-sponsored health insurance and yet, workers may still not get the coverage they want — particularly when it comes to drugs like Wegovy and Novo Nordisk's diabetes drug Ozempic. One in three employees are looking for more resources to combat obesity, according to a recent report by consulting firm Gallagher. Glucagon-like peptide-1 treatments such as Wegovy and Ozempic, which mimic hormones produced in the gut to suppress a person's appetite, are considered game changers on this front. Already, prescription drug costs jumped 8.6% last year, due in part to a surge in the use of GLP-1 drugs, according to a recent report by Mercer. "It becomes a lifelong drug," said Gary Kushner, chair and president of Kushner & Company, a benefits design and management company.

Persons: Gallagher, Trilliant, Mercer, Sunit Patel, actuary, Gary Kushner Organizations: Finance, Security, Kushner & Company Locations: U.S, Mercer's

☆ Novo and Eli contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel'
▼ + stars: | 2024-10-11 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +4 min

Jaap Arriens | NurPhotoDanish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly . Last month, Zealand Pharma announced positive top-line results from a phase 1b trial of its weight-loss drug, a GLP-1/GLP-2 receptor dual agonist called Dapiglutide. Stock Chart Icon Stock chart icon Zealand Pharma. Novo Nordisk is also experimenting with its own version of the treatment, combining the GLP-1 component Semaglutide with amylin analog Cagrilintide in a candidate called CagriSema. Syringes from weight loss drugs "Wegovy," "Ozempic" and "Mounjaro."

Persons: Jaap Arriens, Eli Lilly, Adam Steensberg, Steensberg Organizations: Zealand Pharma, Novo Nordisk, CNBC, pharma, Nordisk, Union, Getty Locations: U.S

Less than a fifth of large companies in the United States include coverage for the popular but pricey weight loss drugs Wegovy and Zepbound in their health insurance plans, according to a survey published Wednesday in Health Affairs. “They’re trying to figure out what is the right balance between the advantages to employees, potential health benefits and the cost of these drugs. The survey found that about half of employers that cover the weight loss drugs have certain requirements associated with their coverage, which Rae said would limit access for some employees but save money. Among large firms that don’t currently cover GLP-1 drugs for weight loss, only about 3% said they’re “very likely” to do so in the next year. Despite the exorbitant cost, employers do have a positive view of the drugs.

Persons: Wegovy, ”, Matthew Rae, “ They’re, —, Rae, Susan Spratt, Christopher McGowan, Eli Lilly, ” McGowan, “, ” Rae, you’ve, that’s, don’t, they’re Organizations: Health Affairs, “ Employers, Population Health Management, Duke Health, Centers for Disease Control, Novo Nordisk, Research, North Carolina, ” Novo Nordisk Locations: United States, KFF, North Carolina, U.S, Novo

All four drugs are in a class of wildly popular weight loss drugs known as GLP-1s. In the United Kingdom, authorities last year seized hundreds of counterfeit Ozempic pens — insulin pens that had been relabeled as Ozempic. Counterfeit weight loss drugs have serious health risks, according to the pharmaceutical companies and federal officials. Counterfeiters are already trying to cash in on a weight loss drug that the company hasn't even put on the market yet: retatrutide. But it's also one of the epicenters of the lucrative counterfeit drug trade, according to U.S. authorities who track counterfeit drugs.

Persons: It's, —, Eli Lilly's Mounjaro, they've, Laver, Andy Morling, CNBC Morling, Eli Lilly, Daniel Skovronsky, Eli Lilly's, we'll, Skovronksy, John F, Sal Ingrassia, Ingrassia, Customs isn't, we've, Yoav Keren, GLP, TikTok, Keren, BrandShield, it's, Nicole Johnson, CNBC Johnson, Johnson, Mike Doustdar, Doustdar, Direnc Bada Organizations: CNBC, U.S, Laver Beauty, DHL, Novo Nordisk, Laver, Medicines, Healthcare Products Regulatory Agency, Lilly Research Labs, Kennedy International, JFK International Mail Facility, U.S . Customs, Border Protection, JFK, CBP, Protection, CNBC CNBC, FDA, Customs, Meta, Facebook, World Health Organization, U.S ., Intellectual, Coordination Center, National, Turkish National Police, Novo Nordisk's, CNBC Counterfeiters, CNBC FDA Locations: BOULDER, COLO, Boulder, Ozempic, Shijiazhuang, China, Beijing, Englewood Cliffs , New Jersey, United Kingdom, London, New York City, U.S, Turkey, Europe, South America, United States, India, Mexico, Istanbul, Zurich

☆ Morgan Stanley's Slimmon says the U.S. infrastructure sector is 'very powerful,' naming a stock to buy
▼ + stars: | 2024-10-07 | by ( Isabella Lok | In Isabellalokys | ) www.cnbc.com time to read: +2 min

Stocks in the infrastructure sector aren't always top of mind. But investors who want to diversify their portfolios away from those popular names and themes can consider the infrastructure theme, says Andrew Slimmon, senior portfolio manager at Morgan Stanley Investment Management. Stock pick Slimmon is bullish on equipment rental company United Rentals . URI YTD mountain YTD shares of United Rentals Shares in United Rentals trade on the New York Stock Exchange, and are up over 40% year to date, and over 80% over the last 12 months. KeyBanc Capital Markets' analysts identified United Rentals as "interesting acquirers," citing its "strong history of driving solid returns through large deals each year."

Persons: Andrew Slimmon, Slimmon, Hurricane Helene, It's, Florida's Organizations: Nvidia, Novo Nordisk, Morgan Stanley Investment Management, United Rentals, New York Stock Exchange, KeyBanc, Markets Locations: U.S, Hurricane, North Carolina , Georgia, Texas, Massachusetts, Bend, Connecticut, North America, Europe, Australia, New Zealand

☆ Bernstein upgrades Campbell as people taking GLP-1 drugs eating more soup
▼ + stars: | 2024-10-07 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Campbell Soup could be poised to benefit from an uptick in GLP-1 drug usage, according to Bernstein. Among the 20 analysts covering Campbell, only five have a strong buy or buy rating, while 12 have a hold rating. In addition, the analyst anticipates that reduced chocolate consumption from GLP-1 intake may hinder U.S. chocolate volumes by 2% to 3%. "Unfortunately, chocolate category volumes remain stubbornly negative and Hershey's chocolate volumes also remain weak despite lapping easier and easier comparables in recent months," Howard continued. Meanwhile, only four have a strong buy or buy rating, and its average target of $202.14 implies a gain of about 5% ahead.

Persons: Campbell, Bernstein, Eli Lilly's Mounjaro, Alexia Howard, Milano, Howard, they've Organizations: Nordisk's Ozempic, Hershey Locations: GLP

☆ 5 Nobel-worthy discoveries that haven’t won the prize
▼ + stars: | 2024-10-05 | by ( Katie Hunt | ) edition.cnn.com time to read: +8 min

The first human genomeThe mapping of the human genome has had a huge impact on biology and other fields. The output from a DNA sequencer is shown in this undated image from the National Human Genome Research Institute. But one reason the project may not have earned a Nobel Prize is the sheer number of people involved in the feat. The Nobel Prize in physiology or medicine will be announced on Monday, followed by the physics prize on Tuesday and the Nobel Prize in chemistry on Wednesday. The Nobel Prize for literature will be announced on Thursday and the Nobel Peace Prize on Friday.

Persons: Alfred Nobel, Nobel, Carsten Snejbjerg, Svetlana Mojsov, Joel Habener, Lotte Bjerre Knudsen —, Lasker, Knudsen, Hassabis, John Jumper, Lester Cohen, David Pendlebury, Pendlebury, “ Nobel, David Baker, ”, Boris Roessler, We’re, Jeffrey Gordon, Robert J, Glaser, Louis, Gordon, Claire King, Barack Obama, Drew Angerer, Mary, King Organizations: CNN, Stockholm —, Human Genome Research, Nordisk, Bloomberg, Getty, Rockefeller University, Harvard Medical School, Novo Nordisk, Clarivate’s Institute for Scientific Information, Google, Institute for Protein, University of Washington School of Medicine, Washington University, of Locations: Swedish, United States, United Kingdom, France, Germany, Japan, China, Hillerød, Denmark, Los Angeles, St

☆ Beyond Novo: Fund manager likes this under-the-radar pharma stock with a weight loss drug in the works
▼ + stars: | 2024-10-04 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

"Maybe that weight loss product (by United Laboratories) works, maybe it doesn't. United Laboratories' price-to-earnings of 5.8 times is a fraction of the 34.3 times that Novo Nordisk is trading at, Peche added. [United Laboratories] is making smooth progress in R & D and targets to launch Liraglutide in 2024. Their comments follow United Laboratories' "faster than expected earnings" growth in the first half of the year. Analysts' average price target on United Laboratories is 12.95 Hong Kong dollars, giving it 28.2% potential upside.

Persons: Sean Peche, it's, Peche, there's, that's, Eli Lilly, Amgen, Carol Dou, Sunny Chen, UOB Kay Hian, bode Organizations: Novo Nordisk, Ranmore Fund Management, United Laboratories, Pfizer, AstraZeneca, Global Equity Fund, Hong, Hong Kong bourse, HK Locations: Hong Kong, Novo, Europe, U.S

☆ Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
▼ + stars: | 2024-10-02 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +2 min

Eli Lilly will spend $4.5 billion to build a center aimed at finding better ways to manufacture its medicines. The facility, called the Lilly Medicine Foundry, will house development of new manufacturing methods with an eye toward efficiency. It's a strategy that's already paying off with Lilly's obesity and weight loss drugs Mounjaro and Zepbound, and Lilly wants it to propel the rest of its pipeline. Lilly says the facility will be the first of its kind to combine research and production in a single location. It will be near a $9 billion manufacturing complex Lilly is building in Lebanon, Indiana, to produce pharmaceutical ingredients like tirzepatide, the active ingredient in Mounjaro and Zepbound.

Persons: Eli Lilly, Mounjaro, Lilly, David Ricks, –, Dan Skovronsky Organizations: Lilly, Foundry, Indianapolis, Novo Nordisk's Ozempic Locations: Indianapolis, Lebanon , Indiana, tirzepatide

☆ Port strike fallout: Blockbuster weight-loss drug supply from Wegovy to Ozempic, Mounjaro, Zepbound caught up in East Coast trade shutdown
▼ + stars: | 2024-10-01 | by ( Lori Ann Larocco | ) www.cnbc.com time to read: +3 min

In this article LLYNOVO.B-DK Follow your favorite stocks CREATE FREE ACCOUNTAn Eli Lilly & Co. Zepbound injection pen, March 28, 2024. Bills of lading, the digital receipts of freight containers, show that the delivery mechanisms for insulin and weight-loss drugs rely on East Coast ports for incoming trade. "Novo Nordisk and Eli Lilly are both heavily reliant on the Port of Norfolk," said William George, director of Research at ImportGenius, which tracks the customs data. Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024. Bloomberg | Bloomberg | Getty ImagesAn Eli Lilly spokesperson said it does not discuss the details of its external supplier relationships.

Persons: Eli Lilly, Eli Lilly — Ozempic, William George, George, Dennis Monts Organizations: Bloomberg, Getty, Novo Nordisk, ILA, Nordisk, Research, U.S . Senate, CNBC, Nuco Logistics Locations: New England, Texas, U.S, lading, East Coast, Port of Norfolk, ImportGenius, Norfolk, airfreight, Hillerod, Denmark, Monts

☆ The one sector of the stock market that is cheap with upside today
▼ + stars: | 2024-09-29 | by ( Karen Firestone | ) www.cnbc.com time to read: +5 min

The table and chart below illustrate some characteristics of the biopharma stocks. The average price/earnings multiple for the group, using 2025 estimates, is 12.7 times versus 20.6 times for the S & P 500. A major knock on the biopharma group is the limited productivity from their extremely expensive research efforts, other than obesity drugs, over the past twenty-five years. The technology using AI might not be ready yet, particularly related to the complex biology of the human body. Complex programs exist already, such as AlphaFold, which predicts the structure of three-dimensional compounds using data on protein sequences.

Persons: Bristol Myers, Amgen, Eli Lilly, Lilly, Johnson Organizations: CNBC, Merck, Pfizer, Novo Nordisk, JPMorgan Locations: Bristol

☆ Insider Today: Austin's genius housing fix
▼ + stars: | 2024-09-28 | by ( Joi-Marie Mckenzie | ) www.businessinsider.com time to read: +7 min

This week's dispatchThe high cost of weight-loss drugsiStock; Rebecca Zisser/BIWhy are two popular weight-loss drugs — Wegovy and diabetes medication Ozempic — so expensive in the US? Patients also bargain-hunt for cheaper weight-loss drugs online, or try to use manufacturer-issued coupons. See the full listiStock; Rebecca Zisser/BIDeals we loveCalling all Madewell shoppers: The bi-annual Madewell Insiders sale is here with 25% off almost everything full-price and an additional 40% off sale. The bi-annual Madewell Insiders sale is here with 25% off almost everything full-price and an additional 40% off sale. The Insider Today team: Dan DeFrancesco, deputy editor and anchor, in New York City.

Persons: —, you've, Shailene Woodley, George Clooney, Rebecca Zisser, Ozempic, Lars Fruergaard Jorgensen, Sen, Bernie Sanders, it's, Gabby Landsverk, Ro, Henry Meds, Eli Lilly, Stefania Pelfini, Jenny Chang, Rodriguez, BI Marie, Mangin, Yellowstone Joey Hadden, Jackson, Wyoming's, Natalie Ammari, Zers, Austin, Tyler Le, Dan DeFrancesco, Jordan Parker Erb, Lisa Ryan, Amanda Yen, Grace Lett Organizations: Business, Service, Novo Nordisk, Federal Trade Commission, FDA, copycats, BI, Yellowstone, Austin, Lone Star, Disney, Pixar, British, Netflix, Insiders Locations: Washington ,, Germany, New York City, New York, Chicago

☆ Move aside, AI: None of our top 5 stocks in the third quarter are in tech
▼ + stars: | 2024-09-27 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

The best-performing Club stocks during the topsy-turvy third quarter are all outside the "Magnificent Seven" and AI-winner complexes. Starbucks: 25.2% New CEO Brian Niccol is the reason why Starbucks' stock is on the list. Best Buy: 18.6% The electronics retailer is another rate-cut winner: More people moving means more purchases of appliances and TVs. In fact, the reasons to own Best Buy are underappreciated by investors, JPMorgan analysts said in a note to clients Friday. Like Stanley Black & Decker and Best Buy, Home Depot is a beneficiary of increased housing sector activity.

Persons: —, Stanley Black, Decker, Brian Niccol, Eli Lilly, Lilly, there's, Jim Cramer's, Jim Cramer, Jim, Donald Allan , Jr, Chris Taylor Organizations: Reserve, Starbucks, Deutsche Bank, GE Healthcare, Novo Nordisk, Abbott Laboratories, Abbott Labs, GE, JPMorgan, CNBC, The New York Stock Exchange, NYSE Global Locations: U.S, China

☆ Stocks making the biggest moves midday: Wynn Resorts, Rocket Lab USA, Cassava Sciences and more
▼ + stars: | 2024-09-27 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

That came after short-seller Hindenburg Research revealed last month it had taken a short position in the company, citing "fresh evidence of accounting manipulation." Cassava Sciences — The biotech company fell 11% after agreeing to pay $40 million to settle a case with the Securities and Exchange Commission. Wynn Resorts — The stock rose about 6% thanks to an upgrade to overweight from equal weight at Morgan Stanley. Amgen — The biotech's shares rose 2% after Cantor Fitzgerald initiated research coverage with an overweight rating. — The aerospace and defense stock added 16% following a price target increase from KeyBanc Capital Markets, which retained an overweight investment rating.

Persons: Bristol Myers, Hindenburg, Morgan Stanley, Amgen, Cantor Fitzgerald, Olivia Brayer, Michael Leshock, — CNBC's Sean Conlon, Alex Harring, Yun Li, Hakyung Kim, Samantha Subin, Pia Singh Organizations: Bristol Myers Squibb, Food and Drug Administration, Bristol, Nordisk —, JPMorgan, Wall, Costco Wholesale, Revenue, Wall Street Journal, Justice Department, Hindenburg Research, Securities and Exchange Commission, Wynn Resorts, UAE, HP Inc, Bank of America, KeyBanc Locations: Nordisk — U.S, Danish, Las Vegas

☆ Stocks making the biggest moves premarket: Bristol-Myers Squibb, Costco, Super Micro Computer and more
▼ + stars: | 2024-09-27 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Costco Wholesale — The membership-only retailer saw shares dip about 1% after the company missed expectations for fiscal fourth-quarter revenue. Super Micro Computer — Shares of the artificial intelligence beneficiary slipped 2%, adding to their 12% loss in the previous session. The Wall Street Journal reported that the U.S. Justice Department had opened a probe on the company. Dollar General — Shares fell 2% after Citi downgraded Dollar General to sell from neutral, saying Walmart 's increasing dominance in retail, especially on pricing, has the dollar store "on the wrong side." HP Inc. — The tech hardware stock fell about 2% after a downgrade to neutral from buy at Bank of America.

Persons: Myers Squibb, Costco, Hindenburg, Morgan Stanley, —, KeyBanc, — CNBC's Hakyung Kim, Lisa Kailai Han, Yun Li, Sarah Min, Jesse Pound, Samantha Subin, Michelle Fox Organizations: Myers, U.S . Food, Drug Administration, Novo Nordisk —, JPMorgan, Costco Wholesale, Revenue, Street Journal, U.S . Justice Department, U.S . Securities, Exchange Commission, Wynn Resorts, Citi, Walmart, HP Inc, Bank of America, HP Locations: Bristol, U.S, Novo Nordisk — U.S, Danish

☆ Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
▼ + stars: | 2024-09-26 | by ( ) www.businessinsider.com time to read: +7 min

A woman who had life-changing results on a popular weight loss drug struggled to afford it for years. AdvertisementTara Rothenhoefer, a 49-year-old Florida resident, says her life changed when she joined a clinical trial for a promising new weight-loss medication. While regulated, these compounded drugs aren't FDA-approved, raising concerns from doctors about variations in quality. The grey market of weight-loss drugs is vast and complicated. In August, Eli Lilly halved the price of its weight-loss drug Zepbound through single-dose vials — a bid to lure customers back to brand-name drugs, analysts said.

Persons: —, Tara Rothenhoefer, Rothenhoefer, Eli Lilly, She's Organizations: Service, Novo Nordisk's, Research, FDA, Pharmaceutical Locations: Florida

☆ Turning point in drug prices is around the corner, says Cantor Fitzgerald's Louise Chen
▼ + stars: | 2024-09-25 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTurning point in drug prices is around the corner, says Cantor Fitzgerald's Louise ChenLouise Chen, Cantor Fitzgerald senior analyst, joins ‘Squawk Box’ to discuss Novo Nordisk's CEO on Capitol Hill, when drug prices could start to come down, and more.

Persons: Cantor Fitzgerald's Louise Chen Louise Chen, Cantor Fitzgerald Organizations: Novo, Capitol

☆ Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
▼ + stars: | 2024-09-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Novo Nordisk 's blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, demonstrating its potential as an alternative treatment for opioid use disorder, according to a new study released Wednesday. The active ingredient in Ozempic, semaglutide, was associated with a "significantly lower" opioid overdose risk than other diabetes medications in people diagnosed with both Type 2 diabetes and opioid use disorder, said the paper published in JAMA Network Open. Around 3,000 people were prescribed semaglutide injections, while the remaining patients received treatments that ranged from insulins to older GLP-1s for diabetes. That reflects a 58% lower risk of opioid overdose in patients who took semaglutide, Xu said.

Persons: Dr, Rong Xu, Eli Lilly, Lilly's, Xu Organizations: Novo Nordisk, JAMA, Case Western Reserve University, Centers for Disease Control, National Center for Drug, U.S, National Institutes of Health, Novo Nordisk's Victoza Locations: London, Britain, Novo

Search resuls for: "Novo Nordisk"

25 mentions found